Search results for "HEP"

showing 10 items of 12243 documents

Hepatocellular carcinoma and direct-acting antivirals: A never ending story?

2017

0301 basic medicinemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsClinical Decision-MakingDIRECT ACTING ANTIVIRALSAntiviral AgentsRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansHepatologybusiness.industryIncidencePatient SelectionLiver NeoplasmsHepatitis C ChronicHepatologymedicine.diseaseLiver TransplantationTreatment Outcome030104 developmental biologyHepatocellular carcinomaCancer research030211 gastroenterology & hepatologyNeoplasm Recurrence Localbusiness
researchProduct

Systemic treatment of HCC in special populations

2020

Summary Recent years have seen significant progress in the systemic treatment of hepatocellular carcinoma (HCC), including the advent of immunotherapy. While several large phase III trials have provided the evidence for a multi-line treatment paradigm, they have focused on a highly selected group of patients by excluding potentially confounding comorbidities. As a result, high quality evidence for the systemic treatment of HCC in patients with various comorbidities is missing. This review summarises current knowledge on the use of approved medicines in patients with HIV, autoimmune disease, cardiovascular disease, diabetes, fibrolamellar HCC, mixed HCC-cholangiocarcinoma, decompensated cirr…

0301 basic medicinemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentComorbidityDisease03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansMultiple Chronic ConditionsAutoimmune diseaseHepatologybusiness.industryLiver NeoplasmsConfoundingDisease ManagementImmunotherapymedicine.diseasedigestive system diseasesPortal vein thrombosis030104 developmental biologyHepatocellular carcinoma030211 gastroenterology & hepatologyMetabolic syndromebusinessJournal of Hepatology
researchProduct

Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress.

2016

Recent studies confirmed a critical importance of c-Met signaling for liver regeneration by modulating redox balance. Here we used liver-specific conditional knockout mice (MetKO) and a nutritional model of hepatic steatosis to address the role of c-Met in cholesterol-mediated liver toxicity. Liver injury was assessed by histopathology and plasma enzymes levels. Global transcriptomic changes were examined by gene expression microarray, and key molecules involved in liver damage and lipid homeostasis were evaluated by Western blotting. Loss of c-Met signaling amplified the extent of liver injury in MetKO mice fed with high-cholesterol diet for 30days as evidenced by upregulation of liver enz…

0301 basic medicinemedicine.medical_specialtyCell SurvivalCholestasis IntrahepaticBiologyToxicologymedicine.disease_causeArticleCholesterol Dietary03 medical and health sciencesMice0302 clinical medicineLiver Function TestsInternal medicinemedicineAnimalsLiver X receptorLiver injuryMice Knockoutmedicine.diagnostic_testLipid metabolismProto-Oncogene Proteins c-metmedicine.diseaseLipid MetabolismGlutathioneLipidsLiver regenerationOxidative Stress030104 developmental biologyEndocrinologyLipotoxicity030220 oncology & carcinogenesisHepatocytesLipid PeroxidationSteatosisLiver function testsOxidative stressSignal TransductionToxicology
researchProduct

Short Term Palmitate Supply Impairs Intestinal Insulin Signaling via Ceramide Production

2016

International audience; The worldwide prevalence of metabolic diseases is increasing, and there are global recommendations to limit consumption of certain nutrients, especially saturated lipids. Insulin resistance, a common trait occurring in obesity and type 2 diabetes, is associated with intestinal lipoprotein overproduction. However, the mechanisms by which the intestine develops insulin resistance in response to lipid overload remain unknown. Here, we show that insulin inhibits triglyceride secretion and intestinal microsomal triglyceride transfer protein expression in vivo in healthy mice force-fed monounsaturated fatty acid-rich olive oil but not in mice force-fed saturated fatty acid…

0301 basic medicinemedicine.medical_specialtyCeramidemedicine.medical_treatmentPalmitic Acid[SDV.BC]Life Sciences [q-bio]/Cellular BiologyPalm OilCeramidesBiochemistryPalmitic acidMice03 medical and health scienceschemistry.chemical_compoundInsulin resistance[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyInternal medicinemedicineAnimalsHumansInsulinPlant OilsIntestinal MucosaPhosphorylationMolecular BiologyComputingMilieux_MISCELLANEOUS2. Zero hungerbiologyTriglycerideInsulinCell BiologyLipid signalingmedicine.diseaseLipids3. Good healthInsulin receptorEnterocytes030104 developmental biologyEndocrinologychemistrySaturated fatty acidbiology.proteinCaco-2 CellsProto-Oncogene Proteins c-akt[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologySignal TransductionJournal of Biological Chemistry
researchProduct

Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors.

2016

Background & Aims The pathomechanisms underlying non-alcoholic fatty liver disease (NAFLD) and the involved molecular regulators are incompletely explored. The nuclear factor-kappa B (NF-κB)-cofactor gene B cell leukemia-3 ( Bcl-3 ) plays a critical role in altering the transcriptional capacity of NF-κB – a key inducer of inflammation – but also of genes involved in cellular energy metabolism. Methods To define the role of Bcl-3 in non-alcoholic steatohepatitis (NASH), we developed a novel transgenic mouse model with hepatocyte-specific overexpression of Bcl-3 ( Bcl-3 Hep ) and employed a high-fat, high-carbohydrate dietary feeding model. To characterize the transgenic model, deep RNA seque…

0301 basic medicinemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentBiology03 medical and health sciencesLiver diseaseMice0302 clinical medicineB-Cell Lymphoma 3 ProteinInternal medicineProto-Oncogene ProteinsmedicineAnimalsHumansInsulinInflammationHepatologyInsulinLiver cellFatty liverLiver Neoplasmsmedicine.disease030104 developmental biologyEndocrinology030220 oncology & carcinogenesisLipogenesisSteatohepatitisSteatosisTranscription FactorsJournal of hepatology
researchProduct

Hepatic benefits of HCV cure

2020

Direct-acting antiviral (DAA)-induced HCV clearance conceivably leads to improved outcomes at all stages of liver disease. However, available data suggest that the maximum measurable benefit is obtained by treating patients before they reach the stage of compensated advanced chronic liver disease (cACLD). Ideally, all patients with chronic hepatitis C should be treated before they develop advanced fibrosis or cirrhosis, since even if sustained virologic response (SVR) reduces the risk of hepatic events (e.g. decompensation and hepatocellular carcinoma [HCC]) and improves survival, further progression of liver disease and adverse outcomes, including hepatic deaths, cannot be entirely avoided…

0301 basic medicinemedicine.medical_specialtyCirrhosisHepatocellular carcinomaPortal venous pressureSurvival.Chronic liver diseaseGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineDecompensationCirrhosiHepatologybusiness.industryHepatitis Cmedicine.diseaseHepatitis Cdigestive system diseases030104 developmental biologyHepatocellular carcinomaPortal hypertension030211 gastroenterology & hepatologybusiness
researchProduct

2017

Background and aims Nonalcoholic fatty liver disease is epidemiologically associated with hepatic and metabolic disorders. The aim of this study was to examine whether hepatic fat accumulation has a causal role in determining liver damage and insulin resistance. Methods We performed a Mendelian randomization analysis using risk alleles in PNPLA3, TM6SF2, GCKR and MBOAT7, and a polygenic risk score for hepatic fat, as instruments. We evaluated complementary cohorts of at-risk individuals and individuals from the general population: 1515 from the liver biopsy cohort (LBC), 3329 from the Swedish Obese Subjects Study (SOS) and 4570 from the population-based Dallas Heart Study (DHS). Results Hep…

0301 basic medicinemedicine.medical_specialtyCirrhosismedicine.diagnostic_testbusiness.industryFatty livermedicine.diseaseChronic liver disease3. Good health03 medical and health sciencesLiver disease030104 developmental biology0302 clinical medicineEndocrinologyInsulin resistanceLiver biopsyInternal medicineNonalcoholic fatty liver diseaseInternal MedicineMedicine030211 gastroenterology & hepatologySteatosisbusinessJournal of Internal Medicine
researchProduct

Antiviral therapy in the palliative setting of HCC (BCLC-B and -C)

2020

The potential impact of direct-acting antivirals (DAAs) in patients with Barcelona Clinic Liver Cancer (BCLC)-B/C stage hepatocellular carcinoma (HCC) is understudied. Patients with HCC have been systematically excluded from randomised controlled trials evaluating the effectiveness of DAAs. Thus, the benefits of DAAs in patients with HCC are less well defined. The presence of active HCC before the initiation of DAA treatment is reported to be a predictor of DAA failure, and studies in patients without HCC have demonstrated that improvements in cirrhosis complications were lower or absent after DAA failure. Even if viral eradication is achieved using DAAs, reversal of liver function impairme…

0301 basic medicinemedicine.medical_specialtyCirrhosisrecurrenceCarcinoma Hepatocellularmedicine.medical_treatmentDecision MakingLiver transplantationAntiviral AgentsRisk Assessment03 medical and health sciences0302 clinical medicineMedicineHumansStage (cooking)HCCIntensive care medicineDAANeoplasm StagingAntiviral Agent...Hepatologybusiness.industryLiver NeoplasmsPalliative CareCancerHepatitis C Chronicmedicine.diseaseBCLC Stage030104 developmental biologyBCLC-Dliver functionHepatocellular carcinoma030211 gastroenterology & hepatologyLiver functionbusinessLiver cancerBCLC-BBCLC-CHuman
researchProduct

Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting

2019

We aimed to provide comprehensive protocols and promote effective management of pregnant women with gynecological cancers. New insights and more experience have been gained since the previous guidelines were published in 2014. Members of the International Network on Cancer, Infertility and Pregnancy (INCIP), in collaboration with other international experts, reviewed existing literature on their respective areas of expertise. Summaries were subsequently merged into a manuscript that served as a basis for discussion during the consensus meeting. Treatment of gynecological cancers during pregnancy is attainable if management is achieved by collaboration of a multidisciplinary team of health c…

0301 basic medicinemedicine.medical_specialtyCognitiveGenital Neoplasms FemaleInternational Cooperation[SDV.CAN]Life Sciences [q-bio]/CancerCancer Chemotherapy Cognitive Gynecologic Offspring Pregnancy[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics03 medical and health sciencesGenital Neoplasms Female/therapyGynecologicOffspring0302 clinical medicineSDG 3 - Good Health and Well-beingPregnancyHealth caremedicinePrenatal Exposure Delayed Effects/etiologyHumansChemotherapyRadiation treatment planningIntensive care medicineSocieties MedicalCancerPregnancy Complications Neoplastic/therapyPregnancyVaginal deliverybusiness.industryCancerHematologymedicine.diseasePrognosis3. Good healthCancer registryLong-term care030104 developmental biologyOncology030220 oncology & carcinogenesisPrenatal Exposure Delayed EffectsPractice Guidelines as TopicFemalePractice Guidelines as Topic/standardsbusinessBreast feedingPregnancy Complications Neoplastic
researchProduct

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis

2021

Background & Aims A number of double, triple, and quadruple therapies have been proposed as first-line empiric treatments for Helicobacter pylori infection. However, knowledge of their worldwide and regional comparative efficacy is lacking. We examined the comparative effectiveness of all empirically used first-line regimens tested against standard triple treatment using a network meta-analysis of published randomized controlled trials. Methods Data extracted from eligible randomized controlled trials were entered into a Bayesian network meta-analysis to investigate the comparative efficacy of H pylori infection empiric first-line regimens and to explore their effectiveness rank order. The …

0301 basic medicinemedicine.medical_specialtyComparative Effectiveness ResearchTime FactorsEfficacyVonoprazanSettore MED/12 - GASTROENTEROLOGIANetwork Meta-Analysislaw.inventionHelicobacter Infections03 medical and health sciences0302 clinical medicineRandomized controlled trialDrug TherapyLevofloxacinlawInternal medicinemedicineHumansFirst-Line RegimensRandomized Controlled Trials as TopicHepatologybiologyHelicobacter pyloribusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyBayes TheoremProton Pump InhibitorsOdds ratioHelicobacter pyloribiology.organism_classificationConfidence intervalAnti-Bacterial AgentsTreatmentRegimen030104 developmental biologyTreatment OutcomeMeta-analysisCombination030211 gastroenterology & hepatologyDrug Therapy Combinationbusinessmedicine.drug
researchProduct